Cargando…

PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8(+) T cell-dependent antitumor immunity and abscopal effect after local irradiation

BACKGROUND: Radiotherapy enhances antitumor immunity. However, it also induces immunosuppressive responses, which are major hurdles for an effective treatment. Thus, targeting the immunosuppressive tumor microenvironment is essential for enhancing the antitumor immunity after radiotherapy. Retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoon, Yi Na, Lee, Eunju, Kwon, Young-Ju, Gim, Jeong-An, Kim, Tae-Jin, Kim, Jae-Sung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Oncolytic and Local Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921929/ https://www.ncbi.nlm.nih.gov/pubmed/35288465 http://dx.doi.org/10.1136/jitc-2021-003762

Ejemplares similares

Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming
por: Aleynick, Mark, et al.
Publicado: (2023)

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade
por: Lee, Won Suk, et al.
Publicado: (2022)

VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects
por: Bazan-Peregrino, Miriam, et al.
Publicado: (2021)

Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma
por: Wang-Bishop, Lihong, et al.
Publicado: (2020)

Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
por: Wang, Weiyi, et al.
Publicado: (2021)

Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
por: Crespo-Rodriguez, Eva, et al.
Publicado: (2020)

Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy
por: Ghonime, Mohammed G, et al.
Publicado: (2021)

Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination
por: Carlson, Peter M, et al.
Publicado: (2023)

Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication
por: Flores, Erica B, et al.
Publicado: (2020)

A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity
por: Huang, Feng-Ying, et al.
Publicado: (2020)

Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity
por: Yu, Xiaofei, et al.
Publicado: (2021)

In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade
por: Mao, Chenkai, et al.
Publicado: (2022)

Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments
por: Bhatta, Maulasri, et al.
Publicado: (2021)

Intratumor childhood vaccine-specific CD4(+) T-cell recall coordinates antitumor CD8(+) T cells and eosinophils
por: Brown, Michael C, et al.
Publicado: (2023)

A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth
por: Gleisner, María Alejandra, et al.
Publicado: (2020)

Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity
por: Taki, Shunichi, et al.
Publicado: (2021)

Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinoma
por: Leb-Reichl, Victoria M, et al.
Publicado: (2021)

Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors
por: Tenesaca, Shirley, et al.
Publicado: (2021)

Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity
por: Seclì, Laura, et al.
Publicado: (2023)

Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity
por: Anfray, Clément, et al.
Publicado: (2021)

CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
por: Puigdelloses, Montserrat, et al.
Publicado: (2021)

Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation
por: Alshebremi, Mohammad, et al.
Publicado: (2023)

Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
por: Zhu, Yu-Chao, et al.
Publicado: (2021)

The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a
por: Peluso, Marisa O, et al.
Publicado: (2020)

Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3α Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity
por: Wang, Jin-Yan, et al.
Publicado: (2022)

An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade
por: Zuo, Shuguang, et al.
Publicado: (2021)

In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models
por: Oba, Takaaki, et al.
Publicado: (2021)

Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer
por: van Vloten, Jacob P, et al.
Publicado: (2022)

Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
por: Hamdan, Firas, et al.
Publicado: (2021)

Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer
por: Lee, Yu Seong, et al.
Publicado: (2020)

STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer
por: Lee, Seung Joon, et al.
Publicado: (2021)

Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade
por: Jung, Bo-Kyeong, et al.
Publicado: (2020)

Recombinant Mycobacterium smegmatis delivering a fusion protein of human macrophage migration inhibitory factor (MIF) and IL-7 exerts an anticancer effect by inducing an immune response against MIF in a tumor-bearing mouse model
por: Jeong, Hyein, et al.
Publicado: (2021)

Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases
por: Yang, Annie, et al.
Publicado: (2023)

Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study
por: Curti, Brendan D, et al.
Publicado: (2022)

Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression
por: Hwang, Bin-Jin, et al.
Publicado: (2022)

In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy
por: Cheng, Yinwen, et al.
Publicado: (2020)

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
por: Siu, Lillian, et al.
Publicado: (2020)

Nanoemulsion adjuvantation strategy of tumor-associated antigen therapy rephrases mucosal and immunotherapeutic signatures following intranasal vaccination
por: Huang, Chung-Hsiung, et al.
Publicado: (2020)

Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy
por: Groeneveldt, Christianne, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oqvg3olj54j0uut5kcch155lkn